A wide range of unregulated chemicals of synthetic origin or derived from natural sources,
which may be a contender for future regulations are called Emerging Contaminants (ECs) …

Covering: 2006 to 2017 Actinomycetes have been, for decades, one of the most important
sources for the discovery of new antibiotics with an important number of drugs and analogs …

Dangerous, antibiotic resistant bacteria have been observed with increasing frequency over
the past several decades. In this review the factors that have been linked to this …

Clostridium difficile epidemiology has changed in recent years, with the emergence of highly
virulent types associated with severe infections, high rates of recurrences and mortality …

Covering: 2011–July 2016 Myxobacteria are a rich source for structurally diverse secondary
metabolites with intriguing biological activities. Here we report on new natural products that …

Transcription of DNA is a fundamental process in all cellular organisms. The enzyme
responsible for transcription, RNA polymerase, is conserved in general architecture and …

Transcription initiation requires formation of the open promoter complex (RPo). To generate
RPo, RNA polymerase (RNAP) unwinds the DNA duplex to form the transcription bubble …

Structure-based drug discovery (SBDD) is an indispensable approach for the design and
optimization of new therapeutic agents. Here, we highlight the rapid progress that has turned …

Mycobacterium tuberculosis (Mtb) is the causative agent of tuberculosis, which kills 1.8
million annually. Mtb RNA polymerase (RNAP) is the target of the first-line antituberculosis …

Fidaxomicin (Fdx) is widely used to treat Clostridioides difficile (Cdiff) infections, but the
molecular basis of its narrow-spectrum activity in the human gut microbiome remains …